MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/410/0.01/20.09.24

MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/410/0.01/20.09.24 Stock

DE000ME4N394

Real-time Bid/Ask 08:34:30 2024-07-02 EDT
0.73 ^EUR / 0.75 ^EUR	+7.25%

Current month	-6.76%
1 month	+23.21%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/410/0.01/20.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	08:34am	BU
Vertex to Announce Second Quarter 2024 Financial Results on August 1	07-01	BU
Verve Therapeutics, Inc. Announces Board Appointments	06-28	CI
Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target	06-27	MT

More news

Quotes 5-day view

Date	Price	Change
24-07-02	0.72	+4.35%
24-07-01	0.69	-6.76%
24-06-28	0.74	+1.37%
24-06-27	0.73	+1.39%
24-06-26	0.72	0.00%

Delayed Quote Börse Stuttgart

Last update July 02, 2024 at 07:59 am

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Morgan Stanley
WKN	ME4N39
ISIN	DE000ME4N394
Date issued	2023-12-05
Strike	410 $
Maturity	2024-09-20 (80 Days)
Parity	100 : 1
Emission price	0.23 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.84 €
Lowest since issue	0.219 €
Delta	0.8x
Omega	4.849
Premium	3.51x
Gearing	6.06x
Moneyness	1.149
Difference Strike	-61.25 $
Difference Strike %	-14.94%
Spread	0.01 €
Spread %	1.37%
Theoretical value	0.7250
Implied Volatility	43.44 %
Total Loss Probability	26.11 %
Intrinsic value	0.5709
Present value	0.1541
Break even	487.78 €
Theta	-0.01x
Vega	0.01x
Rho	0.01x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

471.2 USD

Average target price

468.3 USD

Spread / Average Target

-0.63%

Consensus